WO1997000063A3 - Urocortin peptides - Google Patents

Urocortin peptides Download PDF

Info

Publication number
WO1997000063A3
WO1997000063A3 PCT/US1996/010240 US9610240W WO9700063A3 WO 1997000063 A3 WO1997000063 A3 WO 1997000063A3 US 9610240 W US9610240 W US 9610240W WO 9700063 A3 WO9700063 A3 WO 9700063A3
Authority
WO
WIPO (PCT)
Prior art keywords
ucn
leu
arg
ser
crf
Prior art date
Application number
PCT/US1996/010240
Other languages
French (fr)
Other versions
WO1997000063A2 (en
Inventor
Wylie W Vale Jr
Joan Vaughan
Cynthia J Donaldson
Kathy A Lewis
Paul Sawchenko
Jean E F Rivier
Marilyn H Perrin
Original Assignee
Salk Inst For Biological Studi
Wylie W Vale Jr
Joan Vaughan
Cynthia J Donaldson
Kathy A Lewis
Paul Sawchenko
Jean E F Rivier
Marilyn H Perrin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi, Wylie W Vale Jr, Joan Vaughan, Cynthia J Donaldson, Kathy A Lewis, Paul Sawchenko, Jean E F Rivier, Marilyn H Perrin filed Critical Salk Inst For Biological Studi
Priority to JP50331297A priority Critical patent/JP2002504802A/en
Priority to EP96921584A priority patent/EP0845035A2/en
Priority to US08/981,189 priority patent/US6214797B1/en
Priority to AU62777/96A priority patent/AU6277796A/en
Publication of WO1997000063A2 publication Critical patent/WO1997000063A2/en
Publication of WO1997000063A3 publication Critical patent/WO1997000063A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)

Abstract

Urocortin (Ucn) is a native mammalian peptide generally related to Urotensin I and Corticotropin Releasing Factor (CRF). Human Ucn has the formula: Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2 (SEQ ID NO:15). Rat-derived Ucn is identical but for 2 substitutions, Asp2 for Asn2 and Pro4 for Ser4. Ucn or analogs thereof or pharmaceutically acceptable salts can be administered to humans and other mammals to achieve substantial elevation of ACTH, β-endorphin, β-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone. They can also be used to lower blood pressure over an extended period of time, as stimulants to elevate mood and to improve memory and learning performance, as well as diagnostically. Shortened fragments may be administered to release endogenous CRF and/or Ucn in the brain and peripherally. Ucn antagonists can be used to block the action of Ucn and/or CRF, as can antibodies to Ucn. Labelled Ucn agonists and antagonists can be used in drug screening assays along with CRF receptors; they may also be used diagnostically along with Ucn antibodies.
PCT/US1996/010240 1995-06-13 1996-06-12 Urocortin peptides WO1997000063A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP50331297A JP2002504802A (en) 1995-06-13 1996-06-12 Urocortin peptide
EP96921584A EP0845035A2 (en) 1995-06-13 1996-06-12 Urocortin peptides
US08/981,189 US6214797B1 (en) 1995-06-13 1996-06-12 Urocortin peptides, nucleic acid encoding same methods for using same
AU62777/96A AU6277796A (en) 1995-06-13 1996-06-12 Urocortin peptides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49031495A 1995-06-13 1995-06-13
US08/490,314 1995-06-13
US222395P 1995-08-11 1995-08-11
US60/002,223 1995-08-11

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08/981,189 A-371-Of-International US6214797B1 (en) 1995-06-13 1996-06-12 Urocortin peptides, nucleic acid encoding same methods for using same
US09/818,009 Division US20030032587A1 (en) 1995-06-13 2001-03-26 Urocortin peptides

Publications (2)

Publication Number Publication Date
WO1997000063A2 WO1997000063A2 (en) 1997-01-03
WO1997000063A3 true WO1997000063A3 (en) 1997-01-23

Family

ID=26670100

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/010240 WO1997000063A2 (en) 1995-06-13 1996-06-12 Urocortin peptides

Country Status (5)

Country Link
EP (1) EP0845035A2 (en)
JP (1) JP2002504802A (en)
AU (1) AU6277796A (en)
CA (1) CA2223792A1 (en)
WO (1) WO1997000063A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807504D0 (en) * 1998-04-07 1998-06-10 Univ London Use of corticotropin releasing hormone and like polypeptides in therapy
WO2001072326A1 (en) * 2000-03-31 2001-10-04 Smithkline Beecham Plc Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases
ES2313978T3 (en) * 2000-08-04 2009-03-16 Research Development Foundation UROCORTINE PROTEINS AND ITS USES.
US20020082409A1 (en) * 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
AU2002306853B2 (en) 2001-03-15 2006-07-06 Research Development Foundation Urocortin-III and uses thereof
US7491702B2 (en) 2001-04-18 2009-02-17 The Open University Polypeptides related to amyloid precursor protein, pharmaceutical compositions thereof, and methods of treatment using the same
GB2391548B (en) * 2001-04-18 2005-11-30 Univ Open Polypeptides and derivatives thereof related to amyloid precursor protein (APP)
US7622446B2 (en) 2001-04-18 2009-11-24 The Open University Polypeptides, derivatives and uses thereof
US6936585B2 (en) 2002-01-16 2005-08-30 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
EP2114437A2 (en) 2006-10-16 2009-11-11 ConjuChem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
WO2009043521A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of urocortin iii and urocortin i as therapeutic agents
RU2010113998A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) APPLICATION OF RFMWMR PEPTIDE AS A THERAPEUTIC
JOP20170153A1 (en) * 2016-07-15 2019-01-30 Lilly Co Eli Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease
MX2019004401A (en) 2016-10-20 2019-09-26 Cortene Inc Methods of treating diseases resulting from a maladapted stress response.

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012646A1 (en) * 1988-06-21 1989-12-28 The Salk Institute For Biological Studies Crf analogs
US4908352A (en) * 1987-09-28 1990-03-13 The Salk Institute For Biological Studies Urotensin peptides
WO1990003392A1 (en) * 1988-09-23 1990-04-05 The Salk Institute For Biological Studies Crf antagonists
WO1992022576A1 (en) * 1991-06-14 1992-12-23 The Salk Institute For Biological Studies Crf analogs
WO1995034651A2 (en) * 1994-06-14 1995-12-21 Neurocrine Biosciences, Inc. Corticotropin-releasing factor2 receptors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908352A (en) * 1987-09-28 1990-03-13 The Salk Institute For Biological Studies Urotensin peptides
WO1989012646A1 (en) * 1988-06-21 1989-12-28 The Salk Institute For Biological Studies Crf analogs
WO1990003392A1 (en) * 1988-09-23 1990-04-05 The Salk Institute For Biological Studies Crf antagonists
WO1992022576A1 (en) * 1991-06-14 1992-12-23 The Salk Institute For Biological Studies Crf analogs
WO1995034651A2 (en) * 1994-06-14 1995-12-21 Neurocrine Biosciences, Inc. Corticotropin-releasing factor2 receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
T.W. LOVENBERG ET AL.: "Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, January 1995 (1995-01-01), WASHINGTON US, pages 836 - 840, XP002019808 *
VAUGHAN, JOAN ET AL: "Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor", NATURE (LONDON) (1995), 378(6554), 287-92 CODEN: NATUAS;ISSN: 0028-0836, 16 November 1995 (1995-11-16), XP002019807 *

Also Published As

Publication number Publication date
EP0845035A2 (en) 1998-06-03
AU6277796A (en) 1997-01-15
JP2002504802A (en) 2002-02-12
CA2223792A1 (en) 1997-01-03
WO1997000063A2 (en) 1997-01-03

Similar Documents

Publication Publication Date Title
WO1997000063A3 (en) Urocortin peptides
Kimura et al. Structure-activity relationships of endothelin: importance of the C-terminal moiety
US5157021A (en) Insulin derivatives and pharmaceutical preparations containing these derivatives
AU596968B2 (en) Novel insulin derivatives and pharmaceutical preparations containing these derivatives
Allen et al. Coordinate control of corticotropin, β-lipotropin, and β-endorphin release in mouse pituitary cell cultures
KASAI et al. Determination of the complete amino acid sequence of calmodulin (phenylalanine-rich acidic protein II) from bovine brain
ATE272109T1 (en) RECOMBINANT COLLAGENASE TYPE I FROM CLOSTRIDIUM HISTOLYTICUM AND THE USE THEREOF FOR ISOLATING CELLS AND CELL COMPOUNDS
WO2001025793A3 (en) Diagnosis of coeliac disease using a gliadin epitope
CN102066414A (en) Recombinant FSH including alpha2,3- and alpha2,6-sialylation
DE4142157B4 (en) Opioid peptides, process for their preparation and pharmaceutical compositions containing them
KR920701451A (en) Fusion protein containing an N-terminal fragment of human serum albumin
AU9135691A (en) G protein-coupled glutamate receptors
KR970002917B1 (en) Interleukin-1 inhibitors
KR960704041A (en) Agonists and antagonists of human interleukin-10
WO2000034474A3 (en) Growth factor homolog zvegf3
Carpenter et al. Epidermal growth factors
DK0464105T3 (en) Melanin-concentrating hormones and DNA for expression of the same
McMaster et al. Isolation and amino acid sequence of two urotensin II peptides from Catostomus commersoni urophyses
JPH06503966A (en) Biosynthesized PDGF antagonist
Feyen et al. N-terminal truncation of salmon calcitonin leads to calcitonin antagonists: Structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivo
Eberle Proopiomelanocortin and the melanocortin peptides
Gluschankof et al. The somatostatin-28 convertase of rat brain cortex generates both somatostatin-14 and somatostatin-28 (1–12)
WO2004009614A3 (en) Receptor (sstr4)- selective somatostatin analogs
JPS642572A (en) Polypeptide, dna and use thereof
WO1995006411A1 (en) Method and composition for weight reduction

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2223792

Country of ref document: CA

Ref country code: CA

Ref document number: 2223792

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 08981189

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1996921584

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996921584

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996921584

Country of ref document: EP